Abstract
OBJECTIVE - Type 2 diabetic subjects have an increased propensity to premature atherothrombosis. α-Tocopherol (AT), a potent antioxidant, has anti-inflammatory properties at high doses. The aim of the study was to test the effect of natural (RRR)-AT supplementation (1,200 IU/day) on markers of thrombosis, plasminogen activator inhibitor-1 (PAI-1), and soluble P-selectin (sP-selectin) in type 2 diabetic patients with and without macrovascular complications (MVCs) compared with matched control subjects. RESEARCH DESIGN AND METHODS - The volunteers comprised type 2 diabetic patients with (n = 23) and without (n = 24) MVCs and matched control subjects (n = 25). Plasma levels of PAI-1 and P-selectin were assayed at baseline, after 3 months of supplementation, and after a 2-month washout phase. RESULTS - Both diabetic groups had significantly increased levels of PAI-1 compared with control subjects (P < 0.025), whereas only type 2 diabetic patients with MVCs had significantly elevated levels of sP-selectin compared with control subjects. AT supplementation significantly lowered levels of PAI-1 and sP-selectin in all three groups. The reduction in PAI-1 levels with AT supplementation was significantly greater in type 2 diabetic patients with MVCs than in those without MVCs (P = 0.005). CONCLUSIONS - Thus, AT therapy decreases markers of thrombosis in diabetic patients and control subjects and could be an adjunctive therapy in the prevention of atherosclerosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 524-529 |
| Number of pages | 6 |
| Journal | Diabetes Care |
| Volume | 25 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2002 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. / Devaraj, Sridevi; Cabo Chan, Alberto V.; Jialal, Ishwarlal.
In: Diabetes Care, Vol. 25, No. 3, 03.2002, p. 524-529.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients
AU - Devaraj, Sridevi
AU - Cabo Chan, Alberto V.
AU - Jialal, Ishwarlal
PY - 2002/3
Y1 - 2002/3
N2 - OBJECTIVE - Type 2 diabetic subjects have an increased propensity to premature atherothrombosis. α-Tocopherol (AT), a potent antioxidant, has anti-inflammatory properties at high doses. The aim of the study was to test the effect of natural (RRR)-AT supplementation (1,200 IU/day) on markers of thrombosis, plasminogen activator inhibitor-1 (PAI-1), and soluble P-selectin (sP-selectin) in type 2 diabetic patients with and without macrovascular complications (MVCs) compared with matched control subjects. RESEARCH DESIGN AND METHODS - The volunteers comprised type 2 diabetic patients with (n = 23) and without (n = 24) MVCs and matched control subjects (n = 25). Plasma levels of PAI-1 and P-selectin were assayed at baseline, after 3 months of supplementation, and after a 2-month washout phase. RESULTS - Both diabetic groups had significantly increased levels of PAI-1 compared with control subjects (P < 0.025), whereas only type 2 diabetic patients with MVCs had significantly elevated levels of sP-selectin compared with control subjects. AT supplementation significantly lowered levels of PAI-1 and sP-selectin in all three groups. The reduction in PAI-1 levels with AT supplementation was significantly greater in type 2 diabetic patients with MVCs than in those without MVCs (P = 0.005). CONCLUSIONS - Thus, AT therapy decreases markers of thrombosis in diabetic patients and control subjects and could be an adjunctive therapy in the prevention of atherosclerosis.
AB - OBJECTIVE - Type 2 diabetic subjects have an increased propensity to premature atherothrombosis. α-Tocopherol (AT), a potent antioxidant, has anti-inflammatory properties at high doses. The aim of the study was to test the effect of natural (RRR)-AT supplementation (1,200 IU/day) on markers of thrombosis, plasminogen activator inhibitor-1 (PAI-1), and soluble P-selectin (sP-selectin) in type 2 diabetic patients with and without macrovascular complications (MVCs) compared with matched control subjects. RESEARCH DESIGN AND METHODS - The volunteers comprised type 2 diabetic patients with (n = 23) and without (n = 24) MVCs and matched control subjects (n = 25). Plasma levels of PAI-1 and P-selectin were assayed at baseline, after 3 months of supplementation, and after a 2-month washout phase. RESULTS - Both diabetic groups had significantly increased levels of PAI-1 compared with control subjects (P < 0.025), whereas only type 2 diabetic patients with MVCs had significantly elevated levels of sP-selectin compared with control subjects. AT supplementation significantly lowered levels of PAI-1 and sP-selectin in all three groups. The reduction in PAI-1 levels with AT supplementation was significantly greater in type 2 diabetic patients with MVCs than in those without MVCs (P = 0.005). CONCLUSIONS - Thus, AT therapy decreases markers of thrombosis in diabetic patients and control subjects and could be an adjunctive therapy in the prevention of atherosclerosis.
UR - http://www.scopus.com/inward/record.url?scp=0036511470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036511470&partnerID=8YFLogxK
U2 - 10.2337/diacare.25.3.524
DO - 10.2337/diacare.25.3.524
M3 - Article
C2 - 11874941
AN - SCOPUS:0036511470
VL - 25
SP - 524
EP - 529
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 3
ER -